Original insights, commentary, and expert analysis
In a significant step forward for medical treatments, the European Medicines Agency’s human medicines committee (CHMP) has recommended two innovative
In a significant development within the biopharmaceutical sector, Day One Biopharmaceuticals has made headlines with its acquisition of Mersana Therapeutics,
Neurocrine Biosciences is experiencing a rollercoaster moment in the biopharma sector with its recent announcement regarding the mid-stage clinical trials
Neurocrine Biosciences, a prominent player in the biotechnology sector, recently faced a considerable setback in its quest to advance treatment
As the field of biopharma continues to innovate and advance, Roche has recently made headlines with its experimental drug, fenebrutinib,
The recent acquisition of Metsera by Pfizer is a significant milestone in the realm of obesity drug development, with major
On January 1, 2026, the Centers for Medicare & Medicaid Services (CMS) will introduce a groundbreaking approach to managing Medicaid
The landscape of drug pricing in the United States is at a crucial juncture as the Centers for Medicare &
In a landmark agreement, Novo Nordisk and Eli Lilly have significantly reduced the prices of their obesity drugs, Wegovy and
Moderna, a prominent name in the biopharmaceutical landscape best known for its groundbreaking COVID-19 vaccine, is currently facing a substantial
In recent weeks, the landscape of the obesity treatment market has experienced significant upheaval, following Novo Nordisk’s proposal to acquire
In a significant ruling that reverberates through the pharmaceutical industry, a Delaware Chancery judge has denied Pfizer’s attempt to secure
In the ever-evolving landscape of pharmaceuticals, competition can often be perceived as a threat. However, Bill Sibold, CEO of Madrigal
The introduction of TrumpRx.gov marks a pivotal moment in the healthcare industry, particularly in the realm of pharmaceuticals. Launched under
Eli Lilly, a key player in the pharmaceutical industry, is making waves with its recent announcement of a $3 billion
In the ever-evolving landscape of pharmaceutical developments, the ongoing legal dispute between Pfizer and Novo Nordisk over Metsera highlights the
Eli Lilly has made waves in the pharmaceutical industry with its groundbreaking obesity drug, tirzepatide, sold under the compelling names
As we venture into 2025, the landscape of biotech funding is undergoing dynamic changes. Amid a significant pullback in traditional
The recent decision by the Health Resources and Services Administration (HRSA) to approve eight drug rebate proposals from major pharmaceutical
As we transition into November, the biotechnology and pharmaceutical sectors are abuzz with significant developments that will likely shape the